Clinical Implication of Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-11-03

Study Completion Date

2025-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The retinitis pigmentosa (RP) are genetic conditions that cause retinal degeneration leading to severe low vision and is the leading cause of consultation in reference centers dedicated to the ophthalmic genetics. These rare diseases are characterized by a triple heterogeneity (clinical, genetic and molecular), which made them unreachable by traditional molecular diagnostic sequencing technology by the large number of genes to be tested (\> 190).

The advent of high-throughput sequencing (NGS) and targeted capture has opened unexpected possibilities of investigation and ultimately to improve the care of patients. This project aims to study the genetic and molecular epidemiology of an interregional french (grand EST) cohort of patients. Patients receive a detailed retinal phenotype (visual acuity, visual field, photographs of the fundus and ERG). Their DNA will be analyzed by NGS targets the 190 known genes (https://sph.uth.edu/retnet/).

This research will provide a molecular epidemiological cohort study compared to prior publications on the frequency of genes involved. The benefit for patients is important to: establish a mode of transmission of the disease and optimize genetic counseling (currently very empirical); establish phenotype-genotype correlations in the French population (very few studies to date) and from the data of international literature; identify patients likely to be included in future therapeutic protocols of research; identify patients with significant potential for future projects to identify new genes.

The primary purpose of the protocol is to use high throughput sequencing to identify pathogenic variants in genes involved in RP.

The secondary purposes will be the following:

* Determining the diagnostic yield
* Study the genotype-phenotype correlation.

The secondary purposes will be the following:

* Determining the diagnostic yield
* Study the genotype-phenotype correlation

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A New Diagnostic Paradigm for Retinitis Pigmentosa Secondary to USH2A Pathogenic Variants

NCT06545253

USH2A Variant Retinitis Pigmentosa

NOT_YET_RECRUITING

A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)

NCT06517940

Retinitis Pigmentosa

ACTIVE_NOT_RECRUITING

Biomarkers in Retinitis Pigmentosa

NCT06306690

Retinitis Pigmentosa

RECRUITING

An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa

NCT04868916

X-Linked Retinitis Pigmentosa

COMPLETED

Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures

NCT03845218

Retinitis Pigmentosa

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinitis Pigmentosa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject of both sex, aged at least 2 years, being diagnosed with an RP, and/or having a family history of RP
* Informed about the results of the preliminary medical visit, or which (s) holder (s) parental authority or the guardian / curator has (have) was (been) informed
* Informed consent signed
* Affiliation to the French health system

Exclusion Criteria

* The patient does not want to participate to the protocol
* Intercurrent diseases do not allow the practice of tests provided for this protocol
* Phenocopy
* Subject excluded or being excluded by another protocol
* Subject in emergency case
* Subject under judicial protection

Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes